CVAC - CureVac acquiring Frame Cancer Therapeutics for Euro32 million

Germany-based biopharma CureVac (NASDAQ:CVAC) will acquire privately held, Amsterdam-based Frame Cancer Therapeutics for €32 million (~$34.3M). Frame is developing personalized oncology immunotherapies and considers its approach neoantigen targeted. In January, Dutch authorities approved a trial, FRAME-001, to examine Frame's personalized neoantigen based approach in ~15 patients with non-small-cell lung cancer. CureVac only has one cancer immunotherapy in the clinical phase, CV8102, in phase 1 for melanoma, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, or adenoidcystic carcinoma. Seeking Alpha's Quant Rating views CureVac (CVAC) as a hold.

For further details see:

CureVac acquiring Frame Cancer Therapeutics for €32 million